Literature DB >> 12786761

Endoglin gene mutations and polymorphisms in Italian patients with hereditary haemorrhagic telangiectasia.

P Lastella1, C Sabbà, G M Lenato, N Resta, W Lattanzi, M Gallitelli, A Cirulli, G Guanti.   

Abstract

Autosomal-dominant hereditary haemorrhagic telangiectasia (HHT) is a genetically heterogeneous disease caused by mutations in at least two different loci. We screened for mutations in four Italian families where segregation studies showed clear evidence of linkage to the endoglin (ENG) locus. In addition, one sporadic case and three patients with pulmonary arteriovenous malformations, belonging to small nuclear families unsuitable for linkage analysis, were included in the screening. The proband from each family was investigated using single-strand conformation polymorphism and heteroduplex analysis; potential variants were sequenced. Four novel and one previously reported mutation were detected, as well as three new polymorphisms. The novel mutations included deletions in exon 1 (patient 581/02), exon 5 (patient 780/01) and exon 7 (patient 700/01), and a C-->T229 substitution in exon 3 (patient 462/02). When analysing patient 700/01 and his affected daughter, we encountered a mutant ENG allele with two mutations--a deletion in exon 7 and a substitution in exon 12--which converts isoleucine 575 into threonine, in a non-conserved region. Both mutations were absent in the two healthy sons of the patient, while the polymorphic variant in exon 12 was present in his healthy father. These results and haplotype-segregation studies suggest that a de novo deletion had occurred in the gamete of paternal origin. For the first time the parental germline in which a de novo HHT mutation occurred has been identified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786761     DOI: 10.1034/j.1399-0004.2003.00081.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

Review 1.  Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway.

Authors:  Africa Fernández-L; Francisco Sanz-Rodriguez; Francisco J Blanco; Carmelo Bernabéu; Luisa M Botella
Journal:  Clin Med Res       Date:  2006-03

Review 2.  Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease.

Authors:  S A Abdalla; M Letarte
Journal:  J Med Genet       Date:  2005-05-06       Impact factor: 6.318

3.  Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients.

Authors:  T G W Letteboer; R A Zewald; E J Kamping; G de Haas; J J Mager; R J Snijder; D Lindhout; F A M Hennekam; C J J Westermann; J K Ploos van Amstel
Journal:  Hum Genet       Date:  2004-10-23       Impact factor: 4.132

4.  SMAD4 mutations found in unselected HHT patients.

Authors:  C J Gallione; J A Richards; T G W Letteboer; D Rushlow; N L Prigoda; T P Leedom; A Ganguly; A Castells; J K Ploos van Amstel; C J J Westermann; R E Pyeritz; D A Marchuk
Journal:  J Med Genet       Date:  2006-04-13       Impact factor: 6.318

5.  Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies.

Authors:  Carla Olivieri; Fabio Pagella; Lucia Semino; Luca Lanzarini; Cristina Valacca; Andrea Pilotto; Sabrina Corno; Susi Scappaticci; Guido Manfredi; Elisabetta Buscarini; Cesare Danesino
Journal:  J Hum Genet       Date:  2007-09-05       Impact factor: 3.172

6.  Ocular lesions in hereditary hemorrhagic telangiectasia: genetics and clinical characteristics.

Authors:  Inés Gómez-Acebo; Sara Rodríguez Prado; Ángel De La Mora; Roberto Zarrabeitia Puente; Beatriz de la Roza Varela; Trinidad Dierssen-Sotos; Javier Llorca
Journal:  Orphanet J Rare Dis       Date:  2020-06-29       Impact factor: 4.123

Review 7.  An update on the ophthalmic features in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).

Authors:  Solmaz Abdolrahimzadeh; Martina Formisano; Carla Marani; Siavash Rahimi
Journal:  Int Ophthalmol       Date:  2022-01-16       Impact factor: 2.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.